Journal
REPRODUCTION
Volume 141, Issue 5, Pages 571-580Publisher
BIOSCIENTIFICA LTD
DOI: 10.1530/REP-10-0464
Keywords
-
Categories
Funding
- National Institutes of Health (National Institute of Child Health and Human Development) [R01 HD056034, R01 HD056034-02S1, U54 HD029990, R03 HD061401]
- Hong Kong Research Grants Council [HKU771507, HKU772009]
Ask authors/readers for more resources
Adjudin is a derivative of 1H-indazole-3-carboxylic acid that was shown to have potent anti-spermatogenic activity in rats, rabbits, and dogs. It exerts its effects most notably locally in the apical compartment of the seminiferous epithelium, behind the blood-testis barrier, by disrupting adhesion of germ cells, most notably spermatids to the Sertoli cells, thereby inducing release of immature spermatids from the epithelium that leads to infertility. After adjudin is metabolized, the remaining spermatogonial stem cells and spermatogonia repopulate the seminiferous epithelium gradually via spermatogonial self-renewal and differentiation, to be followed by meiosis and spermiogenesis, and thus fertility rebounds. Recent studies in rats have demonstrated unequivocally that the primary and initial cellular target of adjudin in the testis is the apical ectoplasmic specialization, a testis-specific anchoring junction type restricted to the interface between Sertoli cells and elongating spermatids (from step 8 to 19 spermatids). In this review, we highlight some of the recent advances and obstacles regarding the possible use of adjudin as a male contraceptive. Reproduction (2011) 141 571-580
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available